

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claim 1 (currently amended): A method for inducing hemostasis in a subject, comprising administering to said subject an inducer of P-selectin activity selected from the group consisting of a soluble P-selectin polypeptide and a P-selectin fusion protein, such that hemostasis occurs.

Claims 2-5 (canceled)

Claim 6 (withdrawn): The method of claim 5, wherein the inducer of P-selectin activity is an antibody to a P-selectin receptor or ligand.

Claim 7 (canceled)

Claim 8 (withdrawn): The method of claim 6, wherein the antibody is an antibody to PSGL-1.

Claim 9 (currently amended): A The method of claim 1 for inducing hemostasis in a subject, comprising administering to said subject a soluble P-selectin polypeptide, such that hemostasis occurs.

Claim 10 (withdrawn): A method for inducing hemostasis in a subject, comprising administering to said subject an isolated nucleic acid molecule comprising a nucleotide sequence which encodes a soluble P-selectin polypeptide, such that hemostasis occurs.

Claim 11 (withdrawn): A method for inducing hemostasis in a subject, comprising administering to said subject a recombinant cell expressing soluble P-selectin polypeptide, such that hemostasis occurs.

Claim 12 (currently amended): A method for treating or preventing a disorder associated with hypocoagulation in a subject, comprising administering to said subject an inducer of P-selectin activity selected from the group consisting of a soluble P-selectin polypeptide and a P-selectin fusion protein, such that the disorder associated with hypocoagulation is treated or prevented.

Claim 13 (original): The method of claim 12, wherein said disorder is a hemorrhagic disorder.

Claim 14 (original): The method of claim 12, wherein said disorder is hemophilia.

Claim 15 (original): The method of claim 12, wherein the inducer of P-selectin activity increases the level of soluble P-selectin polypeptide in the plasma of the subject.

Claim 16 (currently amended): A method for treating or preventing a disorder associated with hypocoagulation in a subject, comprising administering to said subject a soluble P-selectin polypeptide selected from the group consisting of a soluble P-selectin polypeptide and a P-selectin fusion protein.

Claim 17 (currently amended): A method for treating a vasculature-associated disease in a subject, comprising administering to said subject an inducer of P-selectin activity selected from the group consisting of a soluble P-selectin polypeptide and a P-selectin fusion protein, such that the vasculature-associated disease is treated.

Claim 18 (original): The method of claim 17, wherein said vasculature-associated disease is a tumor.

Claim 19 (withdrawn): The method of claim 18, wherein said subject is further treated with a molecule effective to induce a procoagulant state in tumor associated vasculature.

Claim 20 (withdrawn): The method of claim 19, wherein said molecule comprises a first binding

region that binds to a component of a tumor cell or tumor associated vasculature, operatively linked to a coagulation factor or a second binding region that binds to a coagulation factor.

Claim 21 (withdrawn): The method of claim 20, wherein said first binding region comprises an antibody, or an antigen binding fragment thereof, that binds to VCAM-1, operatively linked to tissue factor.

Claim 22 (original): The method of claim 17, wherein the inducer of P-selectin activity increases the level of soluble P-selectin polypeptide in the plasma of the subject.

Claims 23-50 (canceled)

Claim 51 (withdrawn): The method of claims 12 or 14, wherein the inducer of P-selectin activity is a fusion protein.

Claim 52 (currently amended): The method of ~~claim 51~~ claims 12 or 14, wherein the P-selectin fusion protein comprises a soluble P-selectin polypeptide operatively linked to an immunoglobulin.

Claim 53 (original): The method of claim 52, wherein the immunoglobulin is a human IgG1, and the Fc region of the immunoglobulin is fused to the C-terminus of at least one soluble P-selectin polypeptide. sequence.

Claim 54 (currently amended): A pharmaceutical composition for administration to a subject *in vivo*, said pharmaceutical composition comprising a P-selectin fusion protein.

Claim 55 (withdrawn): The pharmaceutical composition of claim 53 wherein the fusion protein comprises a soluble P-selectin polypeptide operatively linked to an immunoglobulin.

Claim 56 (withdrawn): The pharmaceutical composition of claim 54 wherein the immunoglobulin is a human IgG1, and the Fc region of the immunoglobulin is fused to the C-terminus of at least one soluble P-selectin polypeptide.

Claim 57 (withdrawn): A pharmaceutical composition for administration to a subject *in vivo*, said pharmaceutical composition comprising a small molecule.